Page is loading...

The Indiana House and Senate Health committees have full plates of issues they’ll be grappling with in the 2020 session of the Indiana General Assembly.

From building on feedback from an extensive summer study committee exploring pricing transparency across the pharmaceutical supply chain, to grappling with a variety of public health concerns, this year’s legislative session is poised to be one of the most impactful on Hoosiers’ healthcare for years to come. Please join us as we get an inside look at how the 2020 session is shaping up and how some specific pieces of legislation may make a big impact on Hoosiers’ healthcare and the state’s life science sector going forward.


Abdul-Hakim Shabazz, Of Counsel, Lewis And Wilkins LLP
Michael O’Connor, Sr. Advisor, State Gov’t Affairs, Eli Lilly and Co.
Bryan Hannon, Director of Indiana Government Relations, American Cancer Society Cancer Action Network (ACS CAN)
George Huntley, CFO, COO Maetrics and member, National Diabetes Volunteer Leadership Council
Pete Seat, Vice President, Bose Public Affairs Group


Kristin Jones, President and CEO, Indiana Health Industry Forum

Questions? Contact Courtney Brown at cbrown@btlaw.com or 317-231-7312.


Trending Connect
We use cookies on this site to enhance your user experience. By clicking any link on this page you are giving your consent for us to use cookies.